Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Blood
Romain GuièzeAnna Schuh

Abstract

Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these mutations or any other, alone or in combination, remains unclear at relapse. The genome of 114 relapsed/refractory patients included in prospective trials was screened using targeted next-generation sequencing of the TP53, SF3B1, ATM, NOTCH1, XPO1, SAMHD1, MED12, BIRC3, and MYD88 genes. We performed clustering according to both number and combinations of recurrent gene mutations. The number of genes affected by mutation was ≥ 2, 1, and 0 in 43 (38%), 49 (43%), and 22 (19%) respectively. Recurrent combinations of ≥ 2 mutations of TP53, SF3B1, and ATM were found in 22 (19%) patients. This multiple-hit profile was associated with a median progression-free survival of 12 months compared with 22.5 months in the remaining patients (P = .003). Concurrent gene mutations are frequent in patients with relapsed/refractory CLL and are associated with worse outcome.

References

Aug 30, 1994·Statistics in Medicine·P GrambschJ D Potter
Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Oct 29, 2010·Genome Research·Gerton Lunter, Martin Goodson
Jun 15, 2011·The Journal of Experimental Medicine·Giulia FabbriGianluca Gaidano
Dec 14, 2011·The New England Journal of Medicine·Lili WangCatherine J Wu
Oct 23, 2012·Blood·David G OscierJonathan C Strefford
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna SkowronskaTatjana Stankovic
Mar 19, 2013·Nature Genetics·Andrew J RamsayCarlos López-Otín
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jun 20, 2014·Leukemia·P BaliakasUNKNOWN European Research Initiative on CLL (ERIC)
Nov 6, 2014·Leukemia·G D Te RaaE Eldering
Jun 13, 2015·Blood·Romain Guièze, Catherine J Wu

❮ Previous
Next ❯

Citations

Oct 16, 2016·Best Practice & Research. Clinical Haematology·Emili MontserratJulio Delgado
Apr 27, 2017·British Journal of Haematology·Hussein GhamlouchOlivier A Bernard
Mar 13, 2017·Blood Reviews·B TessoulinC Pellat-Deceunynck
Jan 20, 2017·Nature Reviews. Disease Primers·Thomas J KippsKanti Rai
Feb 8, 2019·Blood·Satyen H Gohil, Catherine J Wu
Aug 1, 2019·British Journal of Haematology·Kyle CrassiniO Giles Best
Jan 25, 2020·Annual Review of Pathology·Ferran NadeuElías Campo
Oct 21, 2017·Oncotarget·Ana E Rodríguez-VicenteSarka Pospisilova
Aug 4, 2016·Oncotarget·Romain GuièzeAndreï Tchirkov
Aug 23, 2019·Leukemia·Ann-Kathrin DeschAndreas Bräuninger
Aug 11, 2020·American Journal of Hematology·Ludovic JondrevilleFlorence Nguyen-Khac
Jun 2, 2018·Journal of Hematology & Oncology·Enrico DerenziniDavide Treré
Jun 20, 2017·Expert Opinion on Drug Safety·Phu N Tran, Susan O'Brien
Jul 13, 2018·Frontiers in Oncology·Emanuela RosatiPaolo Sportoletti
May 9, 2019·Cancer Medicine·Fotini KostopoulouUNKNOWN French Innovative Leukemia Organization (FILO) group
Nov 29, 2016·Frontiers in Medicine·Gitte WoolerRobert Gniadecki
Aug 5, 2017·British Journal of Haematology·Bian WuThorsten Zenz
Jan 19, 2019·F1000Research·Jörn Bullerdiek, Birgit Rommel
Oct 31, 2015·Blood·Thorsten Zenz, Wolfgang Huber
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory LazarianCatherine J Wu
Nov 11, 2017·Oncoimmunology·Mónica Villa-ÁlvarezSegundo Gonzalez
Jan 9, 2019·Frontiers in Immunology·Mónica Villa-ÁlvarezSegundo Gonzalez
Mar 17, 2020·Current Oncology Reports·Kate MilneTimothy Chevassut
Dec 4, 2016·Hematology·Barbara Eichhorst, Michael Hallek
Apr 10, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nisar A AminSami N Malek
Jun 28, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Basile StamatopoulosAnna Schuh
Jun 3, 2021·Diagnostics·Claudia Pérez-CarreteroJesús María Hernández-Rivas
May 28, 2021·Frontiers in Oncology·Pablo OppezzoNicholas Chiorazzi
Jul 11, 2021·Blood Cancer Journal·Miguel Quijada-ÁlamoJesús-María Hernández-Rivas
Jul 3, 2020·The Journal of Molecular Diagnostics : JMD·Jimmy Lee, Y Lynn Wang
Sep 5, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Kerstin SchottRenate König

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.